
Chinook Therapeutics KDNY
Chinook Therapeutics Total Non Current Liabilities | KDNY
Annual Total Non Current Liabilities Chinook Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 940 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 940 K | 940 K | 940 K |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Фармсинтез
LIFE
|
13.2 M | - | - | - | ||
|
Aclaris Therapeutics
ACRS
|
5.95 M | $ 5.64 | 5.92 % | $ 691 M | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 0.99 | 4.33 % | $ 255 M | ||
|
Alector
ALEC
|
165 M | $ 2.19 | 2.1 % | $ 226 M | ||
|
Aligos Therapeutics
ALGS
|
15 M | $ 5.08 | 0.96 % | $ 50.2 M | ||
|
Alkermes plc
ALKS
|
329 M | $ 45.83 | 0.22 % | $ 7.55 B | ||
|
Allogene Therapeutics
ALLO
|
55.7 M | $ 1.79 | 0.28 % | $ 395 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 248.37 | 0.14 % | $ 32.5 B | ||
|
Altimmune
ALT
|
5.33 M | $ 3.31 | 1.22 % | $ 292 M | ||
|
ALX Oncology Holdings
ALXO
|
5.97 M | $ 1.93 | 0.52 % | $ 104 M | ||
|
Amgen
AMGN
|
37.2 B | $ 380.17 | 0.75 % | $ 205 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 23.96 | 0.74 % | $ 1.12 B | ||
|
Amarin Corporation plc
AMRN
|
31.7 M | $ 14.02 | 1.59 % | $ 5.82 B | ||
|
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 17.23 | 1.29 % | $ 5.4 B | ||
|
AbbVie
ABBV
|
81.7 B | $ 261.94 | 1.87 % | $ 463 B | ||
|
AnaptysBio
ANAB
|
654 K | $ 54.77 | 1.67 % | $ 1.58 B | ||
|
Anika Therapeutics
ANIK
|
26.1 M | $ 21.22 | 1.7 % | $ 304 M | ||
|
ANI Pharmaceuticals
ANIP
|
182 M | $ 70.92 | 1.04 % | $ 1.42 B | ||
|
Aprea Therapeutics
APRE
|
303 K | $ 0.76 | 2.03 % | $ 4.97 M | ||
|
Aptevo Therapeutics
APVO
|
5 M | $ 1.87 | 2.75 % | $ 590 K | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 11.04 | 1.38 % | $ 3.3 B | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.89 | 2.41 % | $ 523 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 15.23 | 3.39 % | $ 417 M | ||
|
Ardelyx
ARDX
|
50.9 M | $ 3.54 | 0.14 % | $ 853 M | ||
|
Armata Pharmaceuticals
ARMP
|
14 M | $ 5.3 | 1.84 % | $ 192 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.35 | 1.95 % | $ 3.1 B | ||
|
Arvinas
ARVN
|
42.1 M | $ 8.44 | 0.41 % | $ 598 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 80.24 | 0.11 % | $ 10.7 B | ||
|
Assembly Biosciences
ASMB
|
18.2 M | $ 28.86 | 0.64 % | $ 324 M | ||
|
Actinium Pharmaceuticals
ATNM
|
682 K | $ 1.25 | 6.87 % | $ 39 M | ||
|
Atara Biotherapeutics
ATRA
|
15.4 M | $ 9.49 | 1.17 % | $ 119 M | ||
|
Agenus
AGEN
|
264 M | $ 7.12 | 2.59 % | $ 212 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
41.9 M | $ 16.3 | 1.26 % | $ 2.19 B | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.94 | 2.93 % | $ 516 M | ||
|
Atea Pharmaceuticals
AVIR
|
69.2 M | $ 5.34 | 0.47 % | $ 435 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 491.2 | 2.47 % | $ 38.4 B | ||
|
Axsome Therapeutics
AXSM
|
48.9 M | $ 216.73 | 0.75 % | $ 10.8 B | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.0 | 0.5 % | $ 12.6 M | ||
|
BridgeBio Pharma
BBIO
|
97.6 M | $ 72.33 | 0.1 % | $ 13.9 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 8.2 | 0.92 % | $ 1.72 B | ||
|
Bicycle Therapeutics plc
BCYC
|
8.18 M | $ 3.87 | 0.13 % | $ 268 M | ||
|
Black Diamond Therapeutics
BDTX
|
7.69 M | $ 2.03 | 2.52 % | $ 115 M | ||
|
Beam Therapeutics
BEAM
|
26 M | $ 24.35 | 1.5 % | $ 2.41 B | ||
|
Biogen
BIIB
|
9.03 B | $ 217.62 | 0.22 % | $ 31.9 B | ||
|
BioLineRx Ltd.
BLRX
|
5.44 M | $ 2.48 | 0.2 % | $ 6.11 B | ||
|
BioMarin Pharmaceutical
BMRN
|
635 M | $ 66.22 | 0.82 % | $ 12.7 B | ||
|
Bristol-Myers Squibb Company
BMY
|
59.9 B | $ 64.03 | 0.61 % | $ 130 B | ||
|
Benitec Biopharma
BNTC
|
213 K | $ 12.11 | 0.08 % | $ 498 M |